138 related articles for article (PubMed ID: 38227082)
1. Co-treatment of silymarin and cisplatin inhibited cell proliferation, induced apoptosis in ovarian cancer.
Karimzadeh MR; Masoudi Chelegahi A; Shahbazi S; Reiisi S
Mol Biol Rep; 2024 Jan; 51(1):118. PubMed ID: 38227082
[TBL] [Abstract][Full Text] [Related]
2. MiR-152 and miR-185 co-contribute to ovarian cancer cells cisplatin sensitivity by targeting DNMT1 directly: a novel epigenetic therapy independent of decitabine.
Xiang Y; Ma N; Wang D; Zhang Y; Zhou J; Wu G; Zhao R; Huang H; Wang X; Qiao Y; Li F; Han D; Wang L; Zhang G; Gao X
Oncogene; 2014 Jan; 33(3):378-86. PubMed ID: 23318422
[TBL] [Abstract][Full Text] [Related]
3. Oleuropein reduces cisplatin resistance in ovarian cancer by targeting apoptotic pathway regulators.
Hashemi Sheikhshabani S; Amini-Farsani Z; Rahmati S; Jazaeri A; Mohammadi-Samani M; Asgharzade S
Life Sci; 2021 Aug; 278():119525. PubMed ID: 33894272
[TBL] [Abstract][Full Text] [Related]
4. MiR-106a targets Mcl-1 to suppress cisplatin resistance of ovarian cancer A2780 cells.
Rao YM; Shi HR; Ji M; Chen CH
J Huazhong Univ Sci Technolog Med Sci; 2013 Aug; 33(4):567-572. PubMed ID: 23904379
[TBL] [Abstract][Full Text] [Related]
5. Glycyrrhizic acid enhances the anticancer activity of cisplatin in the human ovarian cancer cell line.
Omidi F; Shahbazi S; Reiisi S; Azhdari S; Karimzadeh MR
Toxicol In Vitro; 2023 Dec; 93():105687. PubMed ID: 37659683
[TBL] [Abstract][Full Text] [Related]
6. Recovery of miR-139-5p in Ovarian Cancer Reverses Cisplatin Resistance by Targeting C-Jun.
Jiang Y; Jiang J; Jia H; Qiao Z; Zhang J
Cell Physiol Biochem; 2018; 51(1):129-141. PubMed ID: 30439707
[TBL] [Abstract][Full Text] [Related]
7. Baicalein improves the chemoresistance of ovarian cancer through regulation of CirSLC7A6.
Li S; Yi Z; Li M; Zhu Z
J Ovarian Res; 2023 Nov; 16(1):212. PubMed ID: 37940982
[TBL] [Abstract][Full Text] [Related]
8. Long Non-coding RNA CCAT1 Sponges miR-454 to Promote Chemoresistance of Ovarian Cancer Cells to Cisplatin by Regulation of Surviving.
Wang DY; Li N; Cui YL
Cancer Res Treat; 2020 Jul; 52(3):798-814. PubMed ID: 32124583
[TBL] [Abstract][Full Text] [Related]
9. Umbilical Cord Blood-Derived M1 Macrophage Exosomes Loaded with Cisplatin Target Ovarian Cancer
Zhang X; Wang J; Liu N; Wu W; Li H; Lu W; Guo X
Mol Pharm; 2023 Nov; 20(11):5440-5453. PubMed ID: 37819754
[TBL] [Abstract][Full Text] [Related]
10. Synthetic isothiocyanate indole-3-ethyl isothiocyanate (homoITC) enhances sensitivity of human ovarian carcinoma cell lines A2780 and A2780/CP to cisplatin.
Stehlik P; Paulikova H; Hunakova L
Neoplasma; 2010; 57(5):473-81. PubMed ID: 20568902
[TBL] [Abstract][Full Text] [Related]
11. Restoration of microRNA-708 sensitizes ovarian cancer cells to cisplatin via IGF2BP1/Akt pathway.
Qin X; Sun L; Wang J
Cell Biol Int; 2017 Oct; 41(10):1110-1118. PubMed ID: 28685895
[TBL] [Abstract][Full Text] [Related]
12. Icariin regulates the proliferation and apoptosis of human ovarian cancer cells through microRNA-21 by targeting PTEN, RECK and Bcl-2.
Li J; Jiang K; Zhao F
Oncol Rep; 2015 Jun; 33(6):2829-36. PubMed ID: 25845681
[TBL] [Abstract][Full Text] [Related]
13. MiR-27a modulates MDR1/P-glycoprotein expression by targeting HIPK2 in human ovarian cancer cells.
Li Z; Hu S; Wang J; Cai J; Xiao L; Yu L; Wang Z
Gynecol Oncol; 2010 Oct; 119(1):125-30. PubMed ID: 20624637
[TBL] [Abstract][Full Text] [Related]
14. Downregulation of miR-503 contributes to the development of drug resistance in ovarian cancer by targeting PI3K p85.
Wu D; Lu P; Mi X; Miao J
Arch Gynecol Obstet; 2018 Mar; 297(3):699-707. PubMed ID: 29327155
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs.
Chen S; Jiao JW; Sun KX; Zong ZH; Zhao Y
Drug Des Devel Ther; 2015; 9():5225-35. PubMed ID: 26396496
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA-449a reduces cell survival and enhances cisplatin-induced cytotoxicity via downregulation of NOTCH1 in ovarian cancer cells.
Zhou Y; Chen Q; Qin R; Zhang K; Li H
Tumour Biol; 2014 Dec; 35(12):12369-78. PubMed ID: 25179844
[TBL] [Abstract][Full Text] [Related]
17. Berberine in combination with cisplatin induces necroptosis and apoptosis in ovarian cancer cells.
Liu L; Fan J; Ai G; Liu J; Luo N; Li C; Cheng Z
Biol Res; 2019 Jul; 52(1):37. PubMed ID: 31319879
[TBL] [Abstract][Full Text] [Related]
18. Xiaoaiping combined with cisplatin can inhibit proliferation and invasion and induce cell cycle arrest and apoptosis in human ovarian cancer cell lines.
Zheng AW; Chen YQ; Fang J; Zhang YL; Jia DD
Biomed Pharmacother; 2017 May; 89():1172-1177. PubMed ID: 28320083
[TBL] [Abstract][Full Text] [Related]
19. Sequential combination therapy of ovarian cancer with cisplatin and γ-secretase inhibitor MK-0752.
Chen X; Gong L; Ou R; Zheng Z; Chen J; Xie F; Huang X; Qiu J; Zhang W; Jiang Q; Yang Y; Zhu H; Shi Z; Yan X
Gynecol Oncol; 2016 Mar; 140(3):537-44. PubMed ID: 26704638
[TBL] [Abstract][Full Text] [Related]
20. Oridonin effectively reverses cisplatin drug resistance in human ovarian cancer cells via induction of cell apoptosis and inhibition of matrix metalloproteinase expression.
Ma S; Tan W; Du B; Liu W; Li W; Che D; Zhang G
Mol Med Rep; 2016 Apr; 13(4):3342-8. PubMed ID: 26935490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
